Personalized medicine and cancer. - Test2 - elhamkhani - TriplyDB

Personalized medicine and cancer.

Personalized medicine and cancer.

http://www.wikidata.org/entity/Q34608577

about

Germline INDELs and CNVs in a cohort of colorectal cancer patients: their characteristics, associations with relapse-free survival time, and potential time-varying effects on the risk of relapse Biomarkers of HIV-associated Cancer.Cost of illness in colorectal cancer: an international review.Gemini Surfactants Based on Bis-Imidazolium Alkoxy Derivatives as Effective Agents for Delivery of Nucleic Acids: A Structural and Spectroscopic Study Toward clinical genomics in everyday medicine: perspectives and recommendations Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy.A Never Ending Story...The RD-Connect Registry & Biobank Finder: a tool for sharing aggregated data and metadata among rare disease researchers.Which attributes of whole genome sequencing tests are most important to the general population? Results from a German preference study.Development of a Mobile Clinical Prediction Tool to Estimate Future Depression Severity and Guide Treatment in Primary Care: User-Centered Design.

P2860

Q33775249-093E9F1F-C30F-4DFD-9ED4-F0D84D431D81 Q33856851-03E7FCF8-BC40-4450-85AB-B613080EBB2B Q34699421-8002DFFB-ADA0-4770-A6A3-23C41D2A0EF1 Q35862401-AF34D093-D8AC-4C38-9BF7-1B1104445DF0 Q36825747-7F6CA2AF-37A3-4075-982B-468C3EBCE34E Q36931470-6473D9F6-8B83-4743-8169-CD48C62F4DA2 Q38674852-6D16ADC0-3026-4390-8699-36FA5D9B5301 Q44237129-217491E9-0F2F-46BC-AFD2-9F66B92D62B0 Q48112494-243175FD-6837-44DC-91D3-4B05CAE5125B Q50333715-83D4A435-479A-4392-97B8-EC647EDC17F2 Q52568777-43A4D93B-700B-44D8-A5A4-7846D5D54AAB

P2860

Personalized medicine and cancer.

http://www.wikidata.org/entity/Q34608577

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Personalized medicine and cancer.

@ast

Personalized medicine and cancer.

@en

Personalized medicine and cancer.

@nl

type

label

Personalized medicine and cancer.

@ast

Personalized medicine and cancer.

@en

Personalized medicine and cancer.

@nl

prefLabel

Personalized medicine and cancer.

@ast

Personalized medicine and cancer.

@en

Personalized medicine and cancer.

@nl

P1433

Q34608577-F1505861-5F13-472B-8127-09A2F63D8C1A

P1476

Q34608577-2FCD5328-EB5E-4F3F-865F-46BEEA944712

P2093

Q34608577-E40FD292-46C8-41CB-934E-1C8778011799

P2860

Q34608577-01DF4760-3FA0-4F29-9A8D-B3C2ED21EE95

Q34608577-0F1D7E51-9258-49B7-89F6-DAC6F1731581

Q34608577-10E3BFB0-6191-4701-BC33-AE44C152F2CF

Q34608577-121EB534-4805-400E-B01A-AB70CF08BA65

Q34608577-17FD33CE-8BCF-48EC-9D92-FF2D8293691F

Q34608577-1BBE8FB1-419B-4953-B204-9801500EE9CD

Q34608577-1C4B0267-07CE-4261-80BC-896859EC3614

Q34608577-2E90F553-DC05-46F7-B079-BAE9D497881F

Q34608577-3135B6EA-ED82-4448-B146-07F700285631

Q34608577-35A29949-F316-4AC1-ACB2-EB074F56C93A

P304

Q34608577-DFBD693B-28EC-4C55-A97E-0ACAE73EE1C1

P31

Q34608577-8C6C7758-00B4-431A-A777-7079495C1646

P356

Q34608577-2BF16A56-F7A9-4861-9FAF-73A71B2ABDDB

P433

Q34608577-71826C4A-057F-4917-96CC-14C2EDF56679

P478

Q34608577-D755EE0D-4E17-4804-B3C1-E08A7D6FD658

P577

Q34608577-21126FE1-3BB2-453B-85AF-D4892B79A72D

P5875

Q34608577-FA8C3CED-655C-4F71-98FB-FD01F8870ADA

P698

Q34608577-0A3D6F9E-CC2D-4304-86CB-EE0EF6CE41A8

P932

Q34608577-DF71E8CA-F6AD-46AC-A39B-FBA6C3B8EF79

P356

P1433

Journal of personalized medicine

P1476

Personalized medicine and cancer.

@en

P2093

Mukesh Verma

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.

P304

1-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/JPM2010001

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270662949

http://www.w3.org/2001/XMLSchema#string

P698

25562699

http://www.w3.org/2001/XMLSchema#string

P932

4251363

http://www.w3.org/2001/XMLSchema#string